Oculis Stock Gets Increased EPS Estimate from HC Wainwright

Oculis Holding AG (NASDAQ:OCS) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Oculis in a report released on Tuesday, October 20th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.72) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.47) EPS and FY2027 earnings at ($1.90) EPS.

Oculis (NASDAQ:OCS) last announced its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The company had revenue of $0.38 million during the quarter.

OCS has been the topic of a number of other reports. JPMorgan Chase & Co. lowered their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Oculis Price Performance

Oculis stock opened at $7.87 on Thursday. Oculis has a 12 month low of $7.11 and a 12 month high of $34.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The business has a 50 day simple moving average of $10.44 and a 200-day simple moving average of $16.01. The stock has a market capitalization of $456.33 million, a PE ratio of -4.52 and a beta of 0.62.

Institutional Trading of Oculis

Several hedge funds have recently modified their holdings of OCS. Bank of America Corp DE lifted its holdings in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after buying an additional 5,813 shares during the period. Koshinski Asset Management Inc. acquired a new position in Oculis during the first quarter worth $238,000. Himension Capital Singapore PTE. LTD. purchased a new position in Oculis in the first quarter worth $503,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Oculis during the 1st quarter worth $776,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock valued at $854,000 after purchasing an additional 47,158 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.